| Summary of disaggregation of revenue from contracts with customers |
The table below shows the disaggregation of the Group’s revenue from contracts with external customers:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2025 |
|
|
|
Biopharmaceutical and Diagnostic Solutions |
|
|
Engineering |
|
|
Total |
|
|
|
(EUR thousand) |
|
Nature of goods or service |
|
|
|
|
|
|
|
|
|
Revenue from high-value solutions |
|
|
546,374 |
|
|
|
— |
|
|
|
546,374 |
|
Revenue from other containment and delivery solutions |
|
|
491,800 |
|
|
|
— |
|
|
|
491,800 |
|
Revenue from engineering |
|
|
— |
|
|
|
148,108 |
|
|
|
148,108 |
|
Total revenue from contracts with customers |
|
|
1,038,174 |
|
|
|
148,108 |
|
|
|
1,186,282 |
|
|
|
|
|
|
|
|
|
|
|
Geographical markets |
|
|
|
|
|
|
|
|
|
EMEA |
|
|
585,194 |
|
|
|
105,148 |
|
|
|
690,342 |
|
APAC |
|
|
87,715 |
|
|
|
13,764 |
|
|
|
101,479 |
|
North America |
|
|
335,404 |
|
|
|
26,658 |
|
|
|
362,062 |
|
South America |
|
|
29,861 |
|
|
|
2,538 |
|
|
|
32,399 |
|
Total revenue from contracts with customers |
|
|
1,038,174 |
|
|
|
148,108 |
|
|
|
1,186,282 |
|
|
|
|
|
|
|
|
|
|
|
Timing of revenue recognition |
|
|
|
|
|
|
|
|
|
Goods and services transferred at a point in time |
|
|
1,008,476 |
|
|
|
26,751 |
|
|
|
1,035,227 |
|
Goods and services transferred over time |
|
|
29,698 |
|
|
|
121,357 |
|
|
|
151,055 |
|
Total revenue from contracts with customers |
|
|
1,038,174 |
|
|
|
148,108 |
|
|
|
1,186,282 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2024 |
|
|
|
Biopharmaceutical and Diagnostic Solutions |
|
|
Engineering |
|
|
Total |
|
|
|
(EUR thousand) |
|
Nature of goods or service |
|
|
|
|
|
|
|
|
|
Revenue from high-value solutions |
|
|
422,351 |
|
|
|
— |
|
|
|
422,351 |
|
Revenue from other containment and delivery solutions |
|
|
511,391 |
|
|
|
— |
|
|
|
511,391 |
|
Revenue from engineering |
|
|
— |
|
|
|
170,294 |
|
|
|
170,294 |
|
Total revenue from contracts with customers |
|
|
933,742 |
|
|
|
170,294 |
|
|
|
1,104,036 |
|
|
|
|
|
|
|
|
|
|
|
Geographical markets |
|
|
|
|
|
|
|
|
|
EMEA |
|
|
556,324 |
|
|
|
111,506 |
|
|
|
667,830 |
|
APAC |
|
|
83,293 |
|
|
|
12,942 |
|
|
|
96,235 |
|
North America |
|
|
267,520 |
|
|
|
41,429 |
|
|
|
308,948 |
|
South America |
|
|
26,605 |
|
|
|
4,417 |
|
|
|
31,022 |
|
Total revenue from contracts with customers |
|
|
933,742 |
|
|
|
170,294 |
|
|
|
1,104,036 |
|
|
|
|
|
|
|
|
|
|
|
Timing of revenue recognition |
|
|
|
|
|
|
|
|
|
Goods and services transferred at a point in time |
|
|
895,157 |
|
|
|
23,890 |
|
|
|
919,047 |
|
Goods and services transferred over time |
|
|
38,585 |
|
|
|
146,404 |
|
|
|
184,989 |
|
Total revenue from contracts with customers |
|
|
933,742 |
|
|
|
170,294 |
|
|
|
1,104,036 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2023 |
|
|
|
Biopharmaceutical and Diagnostic Solutions |
|
|
Engineering |
|
|
Total |
|
|
|
(EUR thousand) |
|
Nature of goods or service |
|
|
|
|
|
|
|
|
|
Revenue from high-value solutions |
|
|
366,433 |
|
|
|
— |
|
|
|
366,433 |
|
Revenue from other containment and delivery solutions |
|
|
512,855 |
|
|
|
— |
|
|
|
512,855 |
|
Revenue from engineering |
|
|
— |
|
|
|
206,066 |
|
|
|
206,066 |
|
Total revenue from contracts with customers |
|
|
879,288 |
|
|
|
206,066 |
|
|
|
1,085,354 |
|
|
|
|
|
|
|
|
|
|
|
Geographical markets |
|
|
|
|
|
|
|
|
|
EMEA |
|
|
523,681 |
|
|
|
110,366 |
|
|
|
634,047 |
|
APAC |
|
|
76,436 |
|
|
|
26,465 |
|
|
|
102,901 |
|
North America |
|
|
253,870 |
|
|
|
63,666 |
|
|
|
317,536 |
|
South America |
|
|
25,301 |
|
|
|
5,569 |
|
|
|
30,870 |
|
Total revenue from contracts with customers |
|
|
879,288 |
|
|
|
206,066 |
|
|
|
1,085,354 |
|
|
|
|
|
|
|
|
|
|
|
Timing of revenue recognition |
|
|
|
|
|
|
|
|
|
Goods and services transferred at a point in time |
|
|
861,551 |
|
|
|
16,235 |
|
|
|
877,786 |
|
Goods and services transferred over time |
|
|
17,737 |
|
|
|
189,831 |
|
|
|
207,568 |
|
Total revenue from contracts with customers |
|
|
879,288 |
|
|
|
206,066 |
|
|
|
1,085,354 |
|
|